Literature DB >> 28813675

CD44 Interacts with HIF-2α to Modulate the Hypoxic Phenotype of Perinecrotic and Perivascular Glioma Cells.

Elinn Johansson1, Elisa S Grassi1, Vasiliki Pantazopoulou1, Bei Tong1, David Lindgren1, Tracy J Berg1, Elin J Pietras2, Håkan Axelson1, Alexander Pietras3.   

Abstract

Hypoxia-inducible factors enhance glioma stemness, and glioma stem cells have an amplified hypoxic response despite residing within a perivascular niche. Still, little is known about differential HIF regulation in stem versus bulk glioma cells. We show that the intracellular domain of stem cell marker CD44 (CD44ICD) is released at hypoxia, binds HIF-2α (but not HIF-1α), enhances HIF target gene activation, and is required for hypoxia-induced stemness in glioma. In a glioma mouse model, CD44 was restricted to hypoxic and perivascular tumor regions, and in human glioma, a hypoxia signature correlated with CD44. The CD44ICD was sufficient to induce hypoxic signaling at perivascular oxygen tensions, and blocking CD44 cleavage decreased HIF-2α stabilization in CD44-expressing cells. Our data indicate that the stem cell marker CD44 modulates the hypoxic response of glioma cells and that the pseudo-hypoxic phenotype of stem-like glioma cells is achieved by stabilization of HIF-2α through interaction with CD44, independently of oxygen.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD44; HIF-1α; HIF-2α; glioma; hypoxia; hypoxic niche; perivascular niche; stem cell niche; stemness

Mesh:

Substances:

Year:  2017        PMID: 28813675     DOI: 10.1016/j.celrep.2017.07.049

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  33 in total

Review 1.  Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity.

Authors:  Jin Qian; Erinn B Rankin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

2.  SOD2 acetylation and deacetylation: Another tale of Jekyll and Hyde in cancer.

Authors:  Anita B Hjelmeland; Rakesh P Patel
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-06       Impact factor: 11.205

3.  Revealing the glioma cancer stem cell interactome, one niche at a time.

Authors:  Daniel J Silver; Justin D Lathia
Journal:  J Pathol       Date:  2018-02-02       Impact factor: 7.996

4.  What (H)IF isoform matters? A deubiquitinase can tune the hypoxic response.

Authors:  Alexander Pietras
Journal:  EMBO J       Date:  2022-02-24       Impact factor: 11.598

Review 5.  Revisiting the HIF switch in the tumor and its immune microenvironment.

Authors:  Sophie J Cowman; Mei Yee Koh
Journal:  Trends Cancer       Date:  2021-11-04

6.  Hypoxia signaling: Challenges and opportunities for cancer therapy.

Authors:  Mircea Ivan; Melissa L Fishel; Oana M Tudoran; Karen E Pollok; Xue Wu; Paul J Smith
Journal:  Semin Cancer Biol       Date:  2021-10-07       Impact factor: 15.707

7.  HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling.

Authors:  Jie Bai; Wei-Bin Chen; Xiao-Yu Zhang; Xiao-Ning Kang; Li-Jun Jin; Hui Zhang; Zun-Yi Wang
Journal:  World J Stem Cells       Date:  2020-01-26       Impact factor: 5.326

8.  A low MW inhibitor of CD44 dimerization for the treatment of glioblastoma.

Authors:  Chongwu Wang; Zhaotao Wang; Chen Chen; Xiaojun Fu; Ji Wang; Xiaowei Fei; Xiaojing Yan; Ruxiang Xu
Journal:  Br J Pharmacol       Date:  2020-04-05       Impact factor: 8.739

9.  The Anti-Cancer Effects of a Zotarolimus and 5-Fluorouracil Combination Treatment on A549 Cell-Derived Tumors in BALB/c Nude Mice.

Authors:  Ching-Feng Wu; Ching-Yang Wu; Robin Y-Y Chiou; Wei-Cheng Yang; Chuen-Fu Lin; Chao-Min Wang; Po-Hsun Hou; Tzu-Chun Lin; Chan-Yen Kuo; Geng-Ruei Chang
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 10.  The Multifunctional Role of EMP3 in the Regulation of Membrane Receptors Associated with IDH-Wild-Type Glioblastoma.

Authors:  Antoni Andreu Martija; Stefan Pusch
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.